<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00625469</url>
  </required_header>
  <id_info>
    <org_study_id>IPF/PAH</org_study_id>
    <nct_id>NCT00625469</nct_id>
  </id_info>
  <brief_title>Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan</brief_title>
  <official_title>Treatment of Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Hypertension With Bosentan: A Single Center Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajan Saggar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is
      a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting. Currently
      there is no significant data to support the use of pulmonary vasodilators for PAH in the
      setting of interstitial lung disease such as IPF. The majority of IPF patients have PAH
      either at rest or during exercise. The study hypothesis is that bosentan may improve
      morbidity and mortality in the peri-LT setting in both IPF cohorts with either resting or
      exercise PAH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study was to evaluate bosentan in the setting of exercise or resting
      pulmonary hypertension in patients with underlying pulmonary fibrosis.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    competing studies did not allow enrollment
  </why_stopped>
  <start_date type="Actual">October 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 minute walk distance</measure>
    <time_frame>monthly assessement until date of lung transplantation</time_frame>
    <description>ATS Guideline 6MW distance before and after intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>right heart catheterization hemodynamics</measure>
    <time_frame>variable based on time between listing and actual lung transplantation</time_frame>
    <description>pulmonary hemodynamics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chemokine peripheral blood analysis</measure>
    <time_frame>monthly</time_frame>
    <description>battery of chemokines analyzed from the peripheral blood</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>treatment with bosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with resting or exercise induced PAH receive bosentan in a randomized open label fashion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAH group with no therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients with resting or exercise PAH get randomized to receive no specific therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No PAH and no therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients with no evidence of either resting or exercise PAH receive no intervention but are followed until lung transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bosentan</intervention_name>
    <description>62.5mg orally bid for first month, followed by 125mg bid thereafter</description>
    <arm_group_label>treatment with bosentan</arm_group_label>
    <other_name>tracleer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic Pulmonary Fibrosis referred for lung transplantation

          -  Minimum 50 meter 6 minute walk distance

          -  No significant underlying liver disease

        Exclusion Criteria:

          -  Significant liver disease or cirrhosis

          -  non ambulatory

          -  previous adverse reaction/allergy to Bosentan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajan Saggar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David Geffen School of Medicine UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1690</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Departments of Pulmonary and Critical Care, Cardiothoracic Surgery and Infectious Diseases at David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1690</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2008</study_first_submitted>
  <study_first_submitted_qc>February 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2008</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Rajan Saggar</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pulmonary arterial hypertension</keyword>
  <keyword>idiopathic pulmonary fibrosis</keyword>
  <keyword>bosentan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

